Dalerba et al. reported that CDX2 loss might not only identify CRC patients with poorer survival characteristics but also those with an especially aggressive disease course in specific stage groups (e.g. UICC Stage II/III) [17]. Here, CDX2 is linked to colorectal carcinoma.